These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12743133)

  • 1. Use of CA-125 to assess response to new agents in ovarian cancer trials.
    Rustin GJ
    J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
    Rustin GJ; Timmers P; Nelstrop A; Shreeves G; Bentzen SM; Baron B; Piccart MJ; Bertelsen K; Stuart G; Cassidy J; Eisenhauer E
    J Clin Oncol; 2006 Jan; 24(1):45-51. PubMed ID: 16382112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
    Liu PY; Alberts DS; Monk BJ; Brady M; Moon J; Markman M
    J Clin Oncol; 2007 Aug; 25(24):3615-20. PubMed ID: 17704410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
    Tuxen MK; Sölétormos G; Dombernowsky P
    Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
    Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
    J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
    Markman M
    Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
    [No Abstract]   [Full Text] [Related]  

  • 7. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
    Rustin GJ; Vergote I; Eisenhauer E; Pujade-Lauraine E; Quinn M; Thigpen T; du Bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J;
    Int J Gynecol Cancer; 2011 Feb; 21(2):419-23. PubMed ID: 21270624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
    Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
    Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    Markman M; Liu PY; Rothenberg ML; Monk BJ; Brady M; Alberts DS
    J Clin Oncol; 2006 Mar; 24(9):1454-8. PubMed ID: 16549840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 May; 77(2):321-2. PubMed ID: 10785487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
    Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line chemotherapy of epithelial ovarian cancer.
    Markmon M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
    Markman M
    Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second-line chemotherapy and new drugs for ovarian carcinoma].
    Priolo D; Antonelli G; Calì S; Colina P; Giuffrida D; Malaponte E; Mattina M; Parisi A; Sambataro D; Vitale F; Ferraù F
    Clin Ter; 2001; 152(1):39-50. PubMed ID: 11382169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.
    Rustin GJ; Nelstrop AE; Bentzen SM; Bond SJ; McClean P
    J Clin Oncol; 2000 Apr; 18(8):1733-9. PubMed ID: 10764434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
    Smyth JF; Gourley C; Walker G; MacKean MJ; Stevenson A; Williams AR; Nafussi AA; Rye T; Rye R; Stewart M; McCurdy J; Mano M; Reed N; McMahon T; Vasey P; Gabra H; Langdon SP
    Clin Cancer Res; 2007 Jun; 13(12):3617-22. PubMed ID: 17575226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
    Rustin GJ; Bast RC; Kelloff GJ; Barrett JC; Carter SK; Nisen PD; Sigman CC; Parkinson DR; Ruddon RW
    Clin Cancer Res; 2004 Jun; 10(11):3919-26. PubMed ID: 15173101
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
    Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
    J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.